natgillin/translations-raw huggingface dataset:
Clopidogrel Acino Pharma contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Klopidogrel Acino Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično pomembnih neželenih interakcijah.
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of Clopidogrel Acino Pharma;
• če ste alergični na (preobčutljivza klopidogrel ali katerokoli sestavino zdravila
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Sočasno dajanje klopidogrela s peroralnimi antikoagulanti se ne priporoča, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
As a precautionary measure, breast-feeding should not be continued during treatment with clopidogrel.
Iz varnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom ne nadaljuje.
Therefore, concomitant use should be undertaken with caution (see section 4.4).
Zato moramo k sočasni uporabi pristopiti previdno (glejte poglavje 4.4).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as besilate).
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
Clopidogrel Acino Pharma contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products.
Klopidogrel Acino Pharma vsebuje zdravilno učinkovino klopidogrel, ki spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon.
Pri zelo visokih odmerkih so pri podganah in pavijanih poročali tudi o slabem želodčnem prenašanju (gastritis, želodčne erozije in/ali bruhanje).
As a precaution concomitant use strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2).
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (glejte poglavji 4.4 in 5.2).
Clopidogrel Acino Pharma 75 mg film-coated tablets are white to off-white, marbled, round and biconvex.
Klopidogrel Acino Pharma 75 mg tablete so bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene tablete.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujete se z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
- Občasni neželeni učinki: glavobol, razjeda na želodcu, bruhanje, slabost, zaprtost, preveč plinov v želodcu ali črevesju, izpuščaji, srbenje, omotica, občutek mravljinčenja in omrtvelosti.
If you suffer from severe liver disease;
• če imate hudo jetrno obolenje.
PSURs The PSUR submission schedule should follow the PSUR schedule for the reference product.
Redna posodobljena poročila o varnosti zdravila (PSUR) PSUR morajo biti predloženi v skladu s časovnim razporedom za predložitev PSUR za referenčno zdravilo.
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis
Krvavitev v prebavila in retroperitonealna krvavitev s smrtnim izidom, pankreatitis, kolitis (vključno z ulceroznim ali limfocitnim kolitisom), stomatitis
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8.
Drugi aleli, povezani z odsotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in *8 Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah.
NAME OF THE MEDICINAL PRODUCT Clopidogrel Acino Pharma 75 mg film-coated tablets
IME ZDRAVILA Klopidogrel Acino Pharma 75 mg filmsko obložene tablete
Do not use Clopidogrel Acino Pharma after the expiry date which is stated on the carton and on the blister after EXP.
Zdravila Klopidogrel Acino Pharma ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu po oznaki EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Keep out of the reach and sight of children.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
How to store Clopidogrel Acino Pharma Further information
Shranjevanje zdravila Klopidogrel Acino Pharma Dodatne informacije
Clopidogrel Acino Pharma 75 mg film-coated tablets Clopidogrel
Klopidogrel Acino Pharma 75 mg filmsko obložene tablete klopidogrel
What Clopidogrel Acino Pharma looks like and contents of the pack
Izgled zdravila Klopidogrel Acino Pharma in vsebina pakiranja
Do not take Clopidogrel Acino Pharma:
Ne jemljite zdravila Klopidogrel Acino Pharma:
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions)
Zdravilo Klopidogrel Acino Pharma vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (moten krvni pretok v rokah ali nogah, ki ga povzroči zapora žil)
-Very rare side effects:
- Redki neželeni učinki: vrtoglavica.
Each tablet contains 75 mg of clopidogrel (as besilate).
Ena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine.
Pri sočasni uporabi klopidogrela z atenololom, nifedipinom, ali z obema - atenololom in nifedipinom -niso opazili nobenih klinično pomembnih farmakodinamičnih interakcij.
HOW TO TAKE CLOPIDOGREL ACINO PHARMA
KAKO JEMATI ZDRAVILO KLOPIDOGREL ACINO PHARMA
Musculoskeletal , connective tissue and bone disorders
Bolezni mišičnoskeletnega sistema in vezivnega tkiva
Take special care with Clopidogrel Acino Pharma:
Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma:
Ethylcellulose (E462) Titanium dioxide (E 171)
jedro tablete: makrogol 6000 mikrokristalna celuloza (E460) krospovidon (vrsta A) hidrogenirano ricinusovo olje filmska obloga: makrogol 6000 etilceluloza (E462) titanov dioksid (E171)
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as besilate).
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
While you are taking Clopidogrel Acino Pharma:
Ko jemljete zdravilo Klopidogrel Acino Pharma:
This leaflet was last approved in.
Navodilo je bilo odobreno
Always take Clopidogrel Acino Pharma exactly as your doctor has told you.
Pri jemanju zdravila Klopidogrel Acino Pharma natančno upoštevajte zdravnikova navodila.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased
Preiskave krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov
Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Večkratni odmerki po 75 mg na dan tvorijo pomembno zaviranje z ADP sprožene agregacije trombocitov od prvega dne.
Diarrhoea, abdominal pain, indigestion or heartburn.
driska, bolečina v trebuhu, slaba prebava ali zgaga.
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation Esomeprazole is expected to give a similar interaction with clopidogrel.
Povprečno zavrtje agregacije trombocitov se je zmanjšalo za 39 % (začetni odmerek) oz. 21 % (vzdrževalni odmerek).
Excipients
Epistaksa
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Acino Pharma: if you have a risk of bleeding such as a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) a recent serious injury a recent surgery (including dental) a planned surgery (including dental) in the next seven days if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days if you have kidney or liver disease
• če imate tveganje za krvavitev, kot je: zdravstveno stanje s tveganjem za notranjo krvavitev (kot je rana na želodcu) krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa).
Not applicable
Način uporabe
NAME OF THE MEDICINAL PRODUCT Clopidogrel Acino Pharma 75 mg film-coated tablets Clopidogrel NAME OF THE MARKETING AUTHORISATION HOLDER Acino Pharma GmbH EXPIRY DATE
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Acino Pharma GmbH
The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki veljajo, so končne različice, ustvarjene med postopkom koordinacijske skupine.
You might have any of these symptoms and/or conditions.
Pojavi se lahko katerikoli od teh simptomov in/ali stanj.
The overall response rate was 14.1 %.
Povprečna stopnja odzivnosti je bila 14,1 %.
From a microbiological point of view, the product should be used immediately.
Z mikrobiološkega vidika je treba zdravilo uporabiti nemudoma.
Additional medicines:
Dodatna zdravila:
The results of these analyses of efficacy are summarised in the table below:
Izsledki teh analiz učinkovitosti so povzeti v spodnji preglednici:
Date of latest renewal: 20 September 2009
Datum zadnjega podaljšanja: 20. september 2009
This is further supported with data from a clinical study.
To podpirajo tudi podatki iz klinične študije.
Any diarrhoea requiring hospitalisation (irrespective of grade) or grade 3 or 4 diarrhoea.
Kakršnakoli diareja, ki potrebuje hospitalizacijo (ne glede na stopnjo) ali diareja stopnje 3 ali 4
* Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%.
* Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
Between patient variability in clearance is moderate at 19.3 %.
Variabilnost med bolniki v očistku je zmerna, 19,3 %.
The pH of the reconstituted solution is between 6.6 and 7.8.
pH pripravljene raztopine je med 6,6 in 7,8.
Calculate the dose and the number of ALIMTA vials needed.
Izračunajte odmerek in število potrebnih vial zdravila ALIMTA.
Based on the planned date of your infusion of ALIMTA and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Na podlagi načrtovanega datuma vaše infuzije zdravila ALIMTA in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
The doctor or hospital pharmacist will work out the dose you need based on your height and weight.
Zdravnik ali bolnišnični farmacevt bo določil odmerek, ki ga potrebujete, na podlagi vaše telesne višine in mase.
In vitro studies indicate that pemetrexed is approximately 81 % bound to plasma proteins.
Študije in vitro kažejo, da se pemetreksed približno 81 % veže na plazemske beljakovine.
There are many sorts of NSAIDs with different durations of activity.
Obstaja veliko vrst NSAID z različnimi trajanji delovanja.
Creatinine clearance decreased**
Znižan očistek kreatinina**
Fully supplemented patients patients
Bolniki s popolnim bolniki dopolnjevanjem
Fisher's exact p-value*
Fisherjeva točna p-vrednost*
It is not known whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded.
Ni znano, ali se pemetreksed izloča v materino mleko, in neželenih reakcij za dojenčka ne moremo izključiti.
The effect of third space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined.
Učinek tekočine tretjega prostora, denimo plevralnega izliva ali ascitesa, na pemetreksed ni popolnoma opredeljen.
Not known: frequency cannot be estimated from the available data Lower limb swelling with pain and redness Increased urine output
Neznana pogostnost: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov Otekanje spodnjih okončin z bolečino in pordelostjo Povečano izločanje urina
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C to 8°C.
pripravljenega za uporabo, ne uporabimo takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik, in naj bi ne presegali 24 ur pri 2 do 8 °C.
Further dilution is required.
Raztopino moramo še nadalje redčiti.
As a result there is sufficient evidence suggesting a causal relationship between the use of pemetrexed and hyperpigmentation.
Obstaja torej dovolj dokazov, ki kažejo na vzročno povezavo med uporabo pemetrekseda in hiperpigmentacijo.
Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents.
Pri teh bolnikih je potrebna posebna pozornost in previdnost pri uporabi drugih radiosenzitirajočih učinkovin.
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.
Pred začetkom jemanja tega zdravila, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Pharmacotherapeutic group: Folic acid analogues, ATC code: L01BA04
Farmakoterapevtska skupina: Analogi folne kisline, Oznaka ATC: L01BA04
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor.
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 September 2004
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 20. september 2004
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs.
Če niste prepričani, vprašajte zdravnika ali farmacevta, ali je katero od vaših zdravil NSAID.
Log Rank p-value*
Log Rank p-vrednost*
Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy.
Učinkovitost in varnost so merili od časa randomizacije po zaključku terapije prvega izbora (indukcijske terapije).
If you have heart disease or a history of heart disease, please tell your doctor.
Če imate bolezen srca ali če ste v preteklosti imeli bolezen srca, prosimo, povejte to zdravniku.
The total bilirubin should be ≤ 1.5 times upper limit of normal.
Celotni bilirubin mora biti ≤ 1,5-kratnika zgornje meje normalnih vrednosti.
There have been a few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator.
Poročali so o nekaj primerih ekstravazacije pemetrekseda, ki jih raziskovalec ni ocenil kot resne.
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen).
Prosimo, povejte zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes.
Mnogi bolniki, pri katerih so se le-ti pojavili, so imeli v osnovi dejavnike tveganja za razvoj ledvičnih primerov, vključno z dehidracijo ali že prej obstoječo hipertenzijo ali diabetesom.
Creatinine elevation
Povišan kreatinin
The percentage of patients that received post study treatment was 64.3% for ALIMTA and 71.7% for placebo.
Odstotek bolnikov, ki so prejeli zdravljenje po študiji, je bil 64,3 % za zdravilo ALIMTA in 71,7 % za placebo.
Pemetrexed is primarily eliminated in the urine, with 70 % to 90 % of the administered dose being recovered unchanged in urine within the first 24 hours following administration.
Pemetreksed se primarno izloča z urinom, 70 % do 90 % danega odmerka najdemo nespremenjenega v urinu v prvih 24 urah po dajanju.
There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other anti-metabolites, is suspected to cause serious birth defects when administered during pregnancy.
Podatkov o uporabi pemetrekseda pri nosečnicah ni, a za pemetreksed, kot za druge anti-metabolite, sumimo, da povzroča resne prirojene okvare, če ga dajemo med nosečnostjo.
On the basis of the scientific conclusions for pemetrexed the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing pemetrexed is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za pemetreksed odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil, ki vsebujejo pemetreksed, nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Treatment should be resumed according to the guidelines in Table 2.
Z zdravljenjem nadaljujemo skladno s smernicami v Preglednici
ALIMTA is a medicine used in the treatment of cancer.
ALIMTA je zdravilo, ki ga uporabljamo pri zdravljenju raka.
The 1 year and 2 year survival rates for patients on ALIMTA were 58% and 32% respectively, compared to 45% and 21% for patients on placebo.
Stopnji preživetja pri 1 in pri 2 letih pri bolnikih, ki so prejemali zdravilo ALIMTA sta bili 58 % in 32 %, v primerjavi s 45 % in 21 % pri bolnikih, ki so prejemali placebo.
** In the ALIMTA/cisplatin arm, randomized and treated (N = 225) and fully supplemented (N = 167)
**V veji zdravljenja z zdravilom ALIMTA/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with ALIMTA.
Če ste bili nedavno cepljeni, prosimo, povejte to zdravniku saj lahko to ob jemanju zdravila ALIMTA povzroča škodljive učinke.
2 rue du Colonel Lilly 67640 Fegersheim France
2 rue du Colonel Lilly 67640 Fegersheim Francija
Concomitant use not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease.
Odsvetovana sočasna uporaba: Živa oslabljena cepiva (razen proti rumeni mrzlici, za katero je sočasna uporaba kontraindicirana): tveganje za sistemsko, potencialno smrtno bolezen.
The ALIMTA maintenance safety profiles from the two studies JMEN and PARAMOUNT were similar.
Profila varnosti vzdrževalnega zdravljenja z zdravilom ALIMTA iz obeh študij, JMEN in PARAMOUNT, sta bila podobna.
Therefore patients should be cautioned against driving or operating machines if this event occurs.
Zato je treba bolnike opozoriti, da naj ne vozijo in upravljajo strojev, če se pojavi utrujenost.
Response (n: qualified for response) Response rate (%) (95 % CI) Stable disease (%)
Odziv (n: ustrezen za odziv) Stopnja odzivnosti (%) (95 % IZ) Stabilna bolezen (%)
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Povejte zdravniku ali bolnišničnemu farmacevtu, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
In Vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter.
In vitro študije so pokazale, da se pemetreksed aktivno izloča z OAT3 (prenašalcem organskih anionov).
In the data from the originator product, 91 cases of cellulitis, 42 of dermatitis, 13 cases of dermo-hypodermitis, and 3 cases of pseudocellulitis were identified.
Na podlagi podatkov o originatorskem zdravilu so prepoznali 91 primerov celulitisa, 42 primerov dermatitisa, 13 primerov dermohipodermitisa in 3 primere psevdocelulitisa.
Reconstituted and Infusion Solutions: The product should be used immediately.
Rekonstituirane raztopine in raztopine za infundiranje: zdravilo moramo uporabiti nemudoma.
Time to treatment failure (TTTF - months) Median
Čas do neuspeha zdravljenja (Time to treatment failure, TTTF - meseci) Mediana
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Podrobne informacije o tem zdravilu so dostopne na spletni strani Evropske agencije za zdravila EMA http://www.ema.europa.eu.
The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anticancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.
Velika različnost med posamezniki v koagulacijskem statusu v času bolezni ter možnost medsebojnega delovanja med peroralnimi antikoagulacijskimi učinkovinami ter kemoterapijo proti raku zahtevata povečano pogostnost spremljanja INR (International Normalised Ratio), če se odločimo za zdravljenje bolnika s peroralnimi antikoagulacijskimi učinkovinami.
During a periodic regulatory review of the use of pemetrexed a number of cases describing pigmentation disorders has been described with a common frequency.
Med rednim regulatornim pregledom uporabe pemetrekseda so opisali številne primere motenj pigmentacije s pogosto pogostnostjo.
Other medicines and ALIMTA
Druga zdravila in zdravilo ALIMTA
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive ALIMTA.
Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila ALIMTA.
Large cell (N=153)
Velike celice (N = 153)
The dose of ALIMTA is 500 milligrams for every square metre of your body's surface area.
Odmerek zdravila ALIMTA je 500 miligramov za vsak kvadratni meter površine vašega telesa.
rue du Colonel Lilly F-67640 Fegersheim France
rue du Colonel Lilly F-67640, Fegersheim Francija